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ABSTRACT 
 Frank-Ter Haar syndrome (FTHS), Winchester syndrome (WS) and 
multicentric osteolysis, nodulosis, and arthropathy (MONA) are ultra-rare multisystem 
disorders characterized by craniofacial malformations, reduced bone density, skeletal 
and cardiac anomalies, and dermal fibrosis. These autosomal recessive syndromes 
are caused by homozygous mutation or deletion of respectively SH3PXD2B (SH3 
and PX Domains 2B), MMP14 (matrix metalloproteinase 14) or MMP2. Here, we give 
an overview of the clinical features of 63 previously reported patients with 
SH3PXD2B, MMP14 or MMP2 mutation, demonstrating considerable clinical overlap 
between FTHS, WS and MONA. Interestingly, the protein products of SH3PXD2B, 
MMP14 and MMP2 directly cooperate in collagen remodelling. We review animal 
models for these three disorders that accurately reflect the major clinical features and 
likewise show significant phenotypical similarity with each other. Furthermore, they 
demonstrate that defective collagen remodelling is central in the underlying 
pathology. As such, we propose a nosological revision, placing these SH3PXD2B, 
MMP14 and MMP2 related syndromes in a novel “defective collagen-remodelling 
spectrum” (DECORS). In our opinion, this revised nosology better reflects the central 
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DEFINITIONS 
AR, autosomal recessive; BMD, bone mineral density; ECM, extracellular matrix; 
ENU, N-ethyl-N-nitrosourea; FTHS, Frank-Ter Haar syndrome; KO, knockout; MMP, 
matrix metalloproteinase; MONA, multicentric osteolysis, nodulosis, and arthropathy; 
MT-MMP, membrane-type matrix metalloproteinase; MVP, mitral valve prolapse; 
Nee, nose, eye, ear; PI3,4P2, phosphatidylinositol 3,4-bisphosphate; Sabe, small 
and bugged-eyed; SH3PXD2B, SH3 and PX Domains 2B; TKS4, Tyrosine Kinase 
Substrate With Four SH3 Domains; TS, Torg syndrome; VSD, ventricle septum 
defect; WS, Winchester syndrome. 
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INTRODUCTION 
In 1973, Frank et al. described an 18-month-old girl with a newly identified 
multisystem disorder consisting of multiple skeletal anomalies, craniofacial 
dysmorphism, a systolic cardiac murmur and developmental delay [Frank et al. 
1973]. Ter Haar et al. and later Hamel et al. reported four members of a single family 
with a similar phenotype [Hamel et al. 1995; Ter Haar et al. 1982]. Due to multiple 
affected individuals in the reported families, in addition to consanguinity, the absence 
of vertical transmission, and both sexes being equally affected, autosomal recessive 
(AR) inheritance was suggested. [Hamel et al. 1995; Ter Haar et al. 1982]. Maas et 
al. subsequently reported four additional patients. Based on the resemblance with the 
individuals described by Frank et al. and Ter Haar et al., Maas and colleagues 
suggested that all of these patients represent a novel entity that they named Frank-
Ter Haar syndrome (FTHS, MIM 249420) [Maas et al. 2004]. Borrone et al. described 
two brothers with similar features [Borrone et al. 1993]. In these two patients, as well 
as individuals previously diagnosed with FTHS, we identified homozygous mutations 
in SH3PXD2B (MIM #613293) [Wilson et al. 2014].  
Intriguingly, FTHS shows significant clinical overlap with the “vanishing bone” 
syndromes, a group of rare skeletal disorders characterized by excessive bone 
resorption [Martignetti et al. 2001; Sidwell et al. 2004; Zankl et al. 2005]. Historically, 
three different AR multicentric osteolytic syndromes have been distinguished: 
Winchester syndrome (WS, MIM #277950), multicentric osteolysis, nodulosis, and 
arthropathy (MONA, MIM #259600), and Torg syndrome (TS) [Evans et al. 2012; 
Martignetti et al. 2001; Rouzier et al. 2006; Sidwell et al. 2004; Winchester et al. 
1969; Zankl et al. 2005]. These disorders typically present with swelling of the small 
joints of hands and feet causing deformity, with gradual involvement of more proximal 
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joints during early childhood [Martignetti et al. 2001; Prapanpoch et al. 1992; Sidwell 
et al. 2004; Winchester et al. 1969; Zankl et al. 2005]. WS, MONA and TS have been 
considered as distinct entities based on their supposed differences in anatomic 
distribution and severity of the osteolysis, in addition to associated syndromic 
features [Evans et al. 2012; Rouzier et al. 2006; Zankl et al. 2005]. However, 
sequence analysis revealed the presence of homozygous loss-of-function mutations 
in MMP2 (MIM 120360) in patients with clinical diagnoses of WS, MONA, as well as 
TS. Consequently, it was suggested that these three syndromes constitute a 
spectrum [Azzolini et al. 2014; Ekbote et al. 2014; Jeong et al. 2010; Martignetti et al. 
2001; Rouzier et al. 2006; Tuysuz et al. 2009; Zankl et al. 2005; Zankl et al. 2007]. 
Nevertheless, Evans et al. were of the opinion that the phenotype of the two patients 
originally reported by Winchester et al. differed from that of patients with an MMP2 
mutation [Brown et al. 1970; Evans et al. 2012; Winchester et al. 1969]. Subsequent 
genetic analysis of these two individuals identified a homozygous MMP14 missense 
mutation (MIM 600754) [Evans et al. 2012]. In 2007, we reported two patients with a 
phenotype similar to that of the patients described by Borrone et al. [Borrone et al. 
1993; Vanagt et al. 2004; Van Steensel et al. 2007]. However, we did not identify 
deleterious changes of SH3PXD2B or its homolog SH3PXD2A. Rather, we found a 
novel homozygous missense MMP14 mutation in these patients [Wilson et al. 2014]. 
We recently reported that it mostly likely represents a hypomorphic allele [De Vos et 
al. 2018]. 
Since the first mutations were identified in FTHS, MONA and WS patients, 
several additional individuals with a mutation in SH3PXD2B or MMP2 have been 
reported. Here, we give a detailed overview of the clinical features in 63 previously 
published patients with a homozygous SH3PXD2B, MMP2 or MMP14 mutation. We 
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outline the functional connections between SH3PXD2B, MMP2 and MMP14, and 
review current insights in the underlying pathophysiology from in vivo models.  
 
DISCUSSION AND REVIEW 
The clinical features of all documented individuals with a confirmed homozygous 
missense mutation in or deletion of respectively SH3PXD2B (n = 20), MMP14 (n = 4) 
or MMP2 (n = 39) are summarised in Table 1 (see Table SI for details). Most of the 
reported mutations are unique to a single or few families. As expected with AR 
inheritance, roughly half of the reported patients are male [Al Aqeel et al. 2000; Al 
Kaissi et al. 2011; Azzollini et al. 2014; Bader-Meunier et al. 2016; Bendon et al. 2012; 
Bhavani et al. 2016; Borrone et al. 1993; Castberg et al. 2013; Chang et al. 2017; 
Eisenstein et al. 1998; Ekbote et al. 2014; Gok et al. 2010; Hamel et al. 1995; Iqbal et 
al. 2010; Jeong et al. 2010; Maas et al. 2004; Martignetti et al. 2001; Mégarbané et al. 
1997; Phadke et al. 2007; Pichler et al. 2016; Prapanpoch et al. 1992; Rouzier et al. 
2006; Temtamy et al. 2012; Ter Haar et al. 1982; Tuysuz et al. 2009; Vanatka et al. 
2010; Van Steensel et al. 2007; Wilson et al. 2014; Winchester et al. 1969; Zankl et al. 
2005; Zankl et al. 2007; Zrhidri et al. 2017].  
 
CLINICAL OVERLAP BETWEEN FTHS, MONA, AND WS 
In the majority of patients, mutations of SH3PXD2B, MMP14 or MMP2 result in 
a phenotype primarily affecting bone, heart and skin. As mutations in MMP14 have 
only been reported twice, in a total of four patients, statements concerning the effects 
of these mutations need to be interpreted with care.  
Skeletal abnormalitiesBone mineral density (BMD) was reduced in all 
individuals with either an SH3PXD2B, MMP14 or MMP2 mutation in whom BMD was 
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assessed (Table I). Osteolysis was present in all individuals with an SH3PXD2B or 
MMP2 mutation in which it was sought for, in addition to half of the reported patients 
with an MMP14 mutation. A small majority of examined individuals with an MMP2 
mutation had a short stature, in addition to multiple individuals with an SH3PXD2B or 
MMP14 mutation. Brachydactyly was evident in ≥50% of examined individuals with 
mutations in any of the three genes. Kyphoscoliosis has been reported in most 
examined patients with an SH3PXD2B or MMP14 mutation, in addition to several 
individuals with an MMP2 mutation. Other structural anomalies of the vertebral 
column, such as Scheuermann-like changes, are additionally present in multiple 
individuals with an SH3PXD2B, MMP14 or MMP2 mutation. Joint destruction, 
characterized by peri-articular bone loss and erosion of the of the articular surface, 
was present in all examined individuals with an MMP2 mutation, in addition to half of 
the reported patients with an MMP14 mutation. The majority of examined patients 
with an SH3PXD2B, MMP14 or MMP2 mutation had flexion deformities or 
contractures, most often of fingers. Finally, the anterior fontanel was found to be 
prominent in all patients with an SH3PXD2B or MMP14 mutation in which it was 
examined, and open sutures were reported in most of them. These latter two features 
have not been reported for individuals with an MMP2 mutation [Al Aqeel et al. 2000; 
Al Kaissi et al. 2011; Azzollini et al. 2014; Bader-Meunier et al. 2016; Bendon et al. 
2012; Bhavani et al. 2016; Borrone et al. 1993; Castberg et al. 2013; Chang et al. 
2017; Eisenstein et al. 1998; Ekbote et al. 2014; Gok et al. 2010; Hamel et al. 1995; 
Iqbal et al. 2010; Jeong et al. 2010; Maas et al. 2004; Martignetti et al. 2001; 
Mégarbané et al. 1997; Phadke et al. 2007; Pichler et al. 2016; Prapanpoch et al. 
1992; Rouzier et al. 2006; Temtamy et al. 2012; Ter Haar et al. 1982; Tuysuz et al. 
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2009; Vanatka et al. 2010; Van Steensel et al. 2007; Wilson et al. 2014; Winchester 
et al. 1969; Zankl et al. 2005; Zankl et al. 2007; Zrhidri et al. 2017].  
Craniofacial dysmorphismAll reported patients had some degree of 
craniofacial dysmorphism (Fig. 1A and Table I). Most examined individuals with an 
SH3PXD2B, MMP14 or MMP2 mutation had coarse facial features. Brachycephaly 
was present in all examined patients with an SH3PXD2B mutation, in addition to 
several patients with an MMP2 or MMP14 mutation. A prominent forehead and 
hypertelorism were present in all examined patients with an SH3PXD2B or MMP14 
mutation and several individuals with an MMP2 mutation. The palpebral fissures of 
the majority of examined patients with an SH3PXD2B, MMP14 or MMP2 mutation 
were down-slanted. A thick sub-ocular fold was present in the majority of individuals 
with an SH3PXD2B, MMP14 or MMP2 mutation. A flat nasal bridge was observed in 
most examined patients with an SH3PXD2B mutation, but less frequently in patients 
with an MMP14 or MMP2 mutation. Most examined individuals with an SH3PXD2B or 
MMP14 mutation had a broad mouth, as well as one third of examined patients with 
an MMP2 mutation. Finally, thick lips and either a small or heavy mandible have 
been reported in most examined patients with an SH3PXD2B, MMP14 or MMP2 
mutation [Al Aqeel et al. 2000; Al Kaissi et al. 2011; Azzollini et al. 2014; Bader-
Meunier et al. 2016; Bendon et al. 2012; Bhavani et al. 2016; Borrone et al. 1993; 
Castberg et al. 2013; Chang et al. 2017; Eisenstein et al. 1998; Ekbote et al. 2014; 
Gok et al. 2010; Hamel et al. 1995; Iqbal et al. 2010; Jeong et al. 2010; Maas et al. 
2004; Martignetti et al. 2001; Mégarbané et al. 1997; Phadke et al. 2007; Pichler et 
al. 2016; Prapanpoch et al. 1992; Rouzier et al. 2006; Temtamy et al. 2012; Ter Haar 
et al. 1982; Tuysuz et al. 2009; Vanatka et al. 2010; Van Steensel et al. 2007; Wilson 
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et al. 2014; Winchester et al. 1969; Zankl et al. 2005; Zankl et al. 2007; Zrhidri et al. 
2017].  
Ophthalmic anomaliesThe majority of examined individuals with an 
SH3PXD2B mutation, as well as about half of the examined patients with an MMP2 
mutation had prominent eyes (Table I). Corneal opacities, traditionally associated 
with WS, were present in half of the reported patients with an MMP14 mutation, in 
addition to several individuals with an SH3PXD2B or MMP2 mutation [Al Aqeel et al. 
2000; Al Kaissi et al. 2011; Azzollini et al. 2014; Bendon et al. 2012; Bhavani et al. 
2016; Castberg et al. 2013; Chang et al. 2017; Eisenstein et al. 1998; Ekbote et al. 
2014; Gok et al. 2010; Hamel et al. 1995; Iqbal et al. 2010; Jeong et al. 2010; Maas 
et al. 2004; Martignetti et al. 2001; Mégarbané et al. 1997; Phadke et al. 2007; 
Pichler et al. 2016; Prapanpoch et al. 1992; Rouzier et al. 2006; Temtamy et al. 
2012; Ter Haar et al. 1982; Tuysuz et al. 2009; Vanatka et al. 2010; Van Steensel et 
al. 2007; Wilson et al. 2014; Winchester et al. 1969; Zankl et al. 2005; Zankl et al. 
2007; Zrhidri et al. 2017].  
Dental anomaliesGingival hypertrophy has been reported in ≥50% of 
examined individuals with an SH3PXD2B, MMP14 or MMP2 mutation (Table I). 
Delayed dentition, attributed to gingival hypertrophy, was less frequently reported [Al 
Aqeel et al. 2000; Bader-Meunier et al. 2016; Bhavani et al. 2016; Borrone et al. 
1993; Chang et al. 2017; Eisenstein et al. 1998; Ekbote et al. 2014; Martignetti et al. 
2001; Mégarbané et al. 1997; Phadke et al. 2007; Prapanpoch et al. 1992; Temtamy 
et al. 2012; Tuysuz et al. 2009; Van Steensel et al. 2007; Wilson et al. 2014; 
Winchester et al. 1969; Zankl et al. 2007]. 
Cutaneous abnormalitiesAlthough acne is the most common skin disorder in 
the general population, its severity in patients with an SH3PXD2B or MMP14 
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mutation suggests that it might be part of the phenotype (Table I). Acne has not been 
reported in patients with an MMP2 mutation, possibly due to the prepubertal age at 
which these patients were described. Skin thickening has additionally been reported 
in most examined patients with an SH3PXD2B, MMP14 or MMP2 mutation. Notably, 
subcutaneous fibrocollagenous nodules, previously considered as typical for MONA, 
have been observed in patients with a mutation of either SH3PXD2B or MMP14, 
though are more frequent among patients with an MMP2 mutation [Al Aqeel et al. 
2000; Al Kaissi et al. 2011; Azzollini et al. 2014; Bader-Meunier et al. 2016; Bendon 
et al. 2012; Bhavani et al. 2016; Borrone et al. 1993; Castberg et al. 2013; Chang et 
al. 2017; Eisenstein et al. 1998; Ekbote et al. 2014; Gok et al. 2010; Jeong et al. 
2010; Martignetti et al. 2001; Phadke et al. 2007; Pichler et al. 2016; Prapanpoch et 
al. 1992; Rouzier et al. 2006; Temtamy et al. 2012; Tuysuz et al. 2009; Vanatka et al. 
2010; Van Steensel et al. 2007; Wilson et al. 2014; Winchester et al. 1969; Zankl et 
al. 2005; Zankl et al. 2007].  
Cardiac anomaliesMitral valve prolapse (MVP) and/or regurgitation have 
been reported in about half of the examined individuals with an SH3PXD2B mutation, 
in addition to several patients with an MMP14 or MMP2 mutation (Table I). Ventricle 
septum defect (VSD) and outflow tract anomalies have additionally been documented 
in patients with an SH3PXD2B mutation and are less frequent in individuals with an 
MMP2 mutation. These cardiac anomalies caused early childhood death of multiple 
patients [Al Kaissi et al. 2011; Azzollini et al. 2014; Bendon et al. 2012; Bhavani et al. 
2016; Borrone et al. 1993; Castberg et al. 2013; Chang et al. 2017; Ekbote et al. 
2014; Gok et al. 2010; Hamel et al. 1995; Iqbal et al. 2010; Maas et al. 2004; 
Mégarbané et al. 1997; Pichler et al. 2016; Temtamy et al. 2012; Ter Haar et al. 
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1982; Tuysuz et al. 2009; Van Steensel et al. 2007; Wilson et al. 2014; Zrhidri et al. 
2017].  
Developmental delayConsistent with the deformities and joint problems 
described above, about half of the examined patients with an SH3PXD2B, MMP14 or 
MMP2 mutation experienced delayed motor development (Table I). Cognitive 
disability has only been reported in a single patient with an SH3PXD2B mutation, and 
therefore is unlikely to be part of the phenotype [Al Aqeel et al. 2000; Al Kaissi et al. 
2011; Azzollini et al. 2014; Bendon et al. 2012; Borrone et al. 1993; Castberg et al. 
2013; Chang et al. 2017; Eisenstein et al. 1998; Ekbote et al. 2014; Gok et al. 2010; 
Hamel et al. 1995; Iqbal et al. 2010; Jeong et al. 2010; Maas et al. 2004; Martignetti 
et al. 2001; Mégarbané et al. 1997; Phadke et al. 2007; Pichler et al. 2016; 
Prapanpoch et al. 1992; Rouzier et al. 2006; Temtamy et al. 2012; Ter Haar et al. 
1982; Tuysuz et al. 2009; Vanatka et al. 2010; Van Steensel et al. 2007; Wilson et al. 
2014; Winchester et al. 1969; Zankl et al. 2005; Zankl et al. 2007].  
The phenotypic similarities outlined above suggest that FTHS, WS and MONA 
could be considered as parts of a continuous spectrum. Such change in nosology 
reflects the central role of impaired collagen remodelling in the three disorders and is 
supported by the functional connections between the protein products of SH3PXD2B, 




Matrix metalloproteinases (MMPs) are a family of endopeptidases that rely on 
a metal ion for their catalytic activity [Birkedahl-Hansen et al. 1993; Sternlicht et al. 
2001]. In humans, 24 different MMPs have been identified [Strongin 2010]. While the 
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majority are secreted into the extracellular space, the six membrane-type (MT-) 
MMPs are membrane-bound [Massova et al. 1998; Page-McCaw et al. 2007; 
Sternlicht et al. 2001]. All known MMPs are synthesized as latent zymogens that 
require cleavage to achieve activity. MT-MMPs are activated intracellularly and 
soluble MMPs are activated after secretion [Sternlicht et al. 2001]. As their name 
implies, MMPs can hydrolyse almost every structural component of the extracellular 
matrix (ECM) [McKleroy et al. 2013]. In addition, they are able to cleave non-
structural ECM components such as cytokines and growth factors, as well as cell-
surface receptors [Massova et al. 1998]. Each MMP has a distinct yet overlapping 
substrate specificity [Birkedahl-Hansen et al. 1993]. MMPs have been shown to be 
involved in invasion of cells into dense matrices during developmental processes 
such as angiogenesis, primary bone formation and bone remodelling, as well as in 
pathological events such as metastasis. In both cases, MMPs facilitate invasive cell 
motility by degrading the surrounding ECM, including the basement membrane [Chun 
et al. 2004; Hiraoka et al. 1998; Hoshino et al. 2013; Krane et al. 2008; Rundhaug 
2003; Sabeh et al. 2004; Sternlicht et al. 2001]. 
 
SH3PXD2B, MMP14 AND MMP2 FACILITATE INVASIVE CELL MOTILITY BY 
MEDIATING PODOSOME FUNCTION 
MMP14 (also known as MT1-MMP) was the first membrane-bound MMP to be 
discovered [Sato et al. 1994]. It was shown to be widely expressed in many human 
tissues including bone, articular cartilage and skin. In mice, MMP14 is highly 
expressed in (peri-) skeletal tissues during embryonic development [Apte et al. 1997; 
Holmbeck et al. 1999; Kinoh et al. 1996, Rose et al. 2016]. MMP14 is tethered to the 
membrane by a C-terminal transmembrane domain [Koziol et al. 2012; Sato et al. 
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1994; Takino et al. 1995]. It is trafficked through the endoplasmic reticulum, Golgi 
apparatus and trans-Golgi network to specific regions of the plasma membrane 
involved in ECM adhesion, degradation and invasion. These include focal adhesions, 
as well as lamellipodia, filopodia and podosomes at the leading edge of migrating 
cells [Friedl et al. 2009; Koziol et al. 2012; Nakahara et al. 1997; Poincloux et al. 
2009; Sato et al. 1994; Sato et al. 1997; Williams et al. 2012; Zarrabi et al. 2011]. For 
trafficking to podosomes, MMP14 relies on the scaffold protein Src-homology3 (SH3) 
And Phox-homology (PX) Domain-Containing Protein 2B (SH3PXD2B, also known 
as TKS4) [Buschman et al. 2009]. 
MMP14 can hydrolyse a vast array of substrates [Koziol et al. 2012] including 
fibrillar collagen [Hiraoka et al. 1998; McKleroy et al. 2013; Ohuchi et al. 1997; 
d’Ortho et al. 1997; Poincloux et al. 2009; Sternlicht et al. 2001]. MMP14 additionally 
cleaves transmembrane receptors and can thereby alter cellular behaviour [Koziol et 
al. 2012]. For example, digestion of β3-integrin by MMP14 was found to promote 
adhesion and directional migration of MCF-7 cells in vitro [Deryugina et al. 2000]. In 
addition, MMP14 can cleave and thereby activate pro-MMPs, including pro-MMP2 
[Ohuchi et al. 1997; Sato et al. 1994; Takino et al. 1995]. Several animal models 
demonstrated an important role for MMP14-dependent collagen remodelling in the 
resulting phenotype (see below) [Holmbeck et al. 1999; Zhou et al. 2000; De Vos et 
al. 2018]. In addition, we have shown in vitro that MMP14’s ability to activate pro-
MMP2 correlates with disease severity of Winchester syndrome in humans [De Vos 
et al. 2018].  
MMP2 is the most widely expressed metalloproteinase [Rozanov et al. 2001]. 
[Birkedahl-Hansen et al. 1993; Liotta et al. 1979]. It is secreted into the extracellular 
space as an inactive zymogen (pro-MMP2), and subsequently activated by 
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membrane-bound MMP14 [Emonard et al. 1992; Evans et al. 2012; Krane et al. 
2008; Sternlicht et al. 2001; Takino et al. 1995]. Activated MMP2 can degrade 
fragments of fibrillar collagen cleaved by other MMPs such as MMP14 [McKleroy et 
al. 2013]. In doing so, MMP2 directly cooperates with MMP14 and augments its 
collagenolytic activity [Ohuchi et al. 1997; Sato et al. 1994; Takino et al. 1995]. The 
relevance of MMP2 activity is reflected by the overlap between the MMP14 and 
MMP2-related human phenotypes, as outlined above [Al Aqeel et al. 2000; Al Kaissi 
et al. 2011; Azzollini et al. 2014; Bader-Meunier et al. 2016; Bhavani et al. 2016; 
Castberg et al. 2013; De Vos et al. 2018; Eisenstein et al. 1998; Ekbote et al. 2014; 
Gok et al. 2010; Jeong et al. 2010; Martignetti et al. 2001; Phadke et al. 2007; Pichler 
et al. 2016; Rouzier et al. 2006; Temtamy et al. 2012; Tuysuz et al. 2009; Vanatka et 
al. 2010; Zankl et al. 2005; Zankl et al. 2007]. 
MMP14, MMP2 and SH3PXD2B are all present at podosomes, specialized 
membrane structures that are transiently formed by cell types whose roles require 
invasive motility, including osteoclasts, macrophages and endothelial cells. Invasive 
cancer cells and viral oncogene-transformed fibroblasts form similar structures called 
invadopodia [Buschman et al. 2009; Gawden-Bone et al. 2010; Hoshino et al. 2013; 
Linder et al. 2005; Murphy et al. 2011; Seano et al. 2014]. In contrast to MMP14 and 
MMP2, SH3PXD2B has no catalytic activity but rather helps facilitate invadopodia 
and podosome formation. In 2D culture, podosomes and invadopodia present as 
dome-shaped membrane protrusions at the surface that is in contact with the matrix 
or coating on which the cell is growing. Whereas podosomes are present at the 
leading edge of the cell and are typically 0.5-2 µm in size, invadopodia can achieve 
larger dimensions and are primarily found underneath the nucleus [Gawden-Bone et 
al. 2010; Linder et al. 2005; Murphy et al. 2011]. Despite this difference in size and 
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location, both have a highly similar molecular composition [Buschman et al. 2009]. 
Ultra-structurally, they consist of a core surrounded by the so-called ring region. The 
core region contains filamentous actin and associated proteins regulating actin 
polymerisation. The ring contains integrins, integrin-binding and signalling proteins, 
along with MMP14 and scaffolding proteins including SH3PXD2B and its homolog 
SH3PXD2A [Buschman et al. 2009; Gawden-Bone et al. 2010; Lanyi et al. 2011; 
Linder et al. 2005; Murphy et al. 2011]. In mice, expression of Sh3pxd2b was 
demonstrated to be highest in 11 to 17-day-old embryos. It is widely expressed in 
adult tissues [Buschman et al. 2009].  
The formation of podosomes is a multistep process, summarized in Figure 2A 
and reviewed in detail elsewhere [Murphy et al. 2011; Hosino et al. 2013]. Briefly, 
during podosome maturation, SH3PXD2B, MMP14 and MMP2 cooperate to activate 
the freshly formed structure. SH3PXD2B recruits active MMP14 from intracellular 
stores to the nascent podosome membrane, where MMP14 subsequently cleaves 
secreted pro-MMP2 (Fig. 2A(iii)). Together, MMP14 and MMP2 initiate focal 
pericellular ECM degradation [Bendon et al. 2012; Buschman et al. 2009; Iqbal et al. 
2010; Massova et al. 1998; Murphy et al. 2011; Poincloux et al. 2009].  
The functional link between SH3PXD2B, MMP14 and MMP2 is further 
highlighted by the (partially) overlapping phenotypes of several mutant animal 
models that have been respectively identified or generated. Investigations utilising 
these animal models furthermore provided novel insights in the processes underlying 
the skeletal phenotype.  
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MUTATION OR KNOCKOUT OF MMP14 IN MICE AND ZEBRAFISH RESULTS IN 
PHENOTYPES THAT STRONGLY RESEMBLE WS 
There are two mouse models with homozygous Mmp14 missense mutations. 
The Sabe (small and bugged-eyed) mutation (p.R92C) arose spontaneously in the 
C57BL/6J background (Fig. 1B(i)), whereas the Cartoon mutation (p.S466P) was 
serendipitously recovered in an N-ethyl-N-nitrosourea (ENU) screen aimed at 
identifying immunological phenotypes in the C57BL/6J background (Fig. 1B(ii)) 
[Curtain et al. 2012; Du et al. 2013]. These different mutations in Mmp14 result in a 
near identical phenotype, which is similar to that of Mmp14 knockout (KO) mice and, 
importantly, shares key aspects with that of WS patients (Fig. 1B(iii)) [Gutierrez-
Fernandez et al. 2015; Holmbeck et al. 1999; Zhou et al. 2000]. Interestingly, in 
zebrafish (Danio rerio), knockout of mmp14a/b also results in a constellation of 
abnormalities that strongly resembles WS including short stature, thoracic kyphosis, 
reduced BMD and craniofacial dysmorphology (Fig. 1C(i)) [De Vos et al. 2018]. All 
models have a gradually worsening phenotype encompassing short stature, 
progressively reduced BMD, thoracic kyphosis and craniofacial dysmorphology 
affecting the forehead, midface and jaw [Curtain et al. 2012; De Vos et al. 2018; Du 
et al. 2013; Gutierrez-Fernandez et al. 2015; Holmbeck et al. 1999; Van Steensel et 
al. 2007; Winchester et al. 1969; Zhou et al. 2000]. Interestingly, they also exhibit 
features not observed in humans, including early death due to wasting in the mice, 
respectively foramen magnum stenosis with spinal cord impingement in the fish 
[Curtain et al. 2012; De Vos et al. 2018; Du et al. 2013]. 
In Mmp14 KO mice and mmp14a/b KO fish the early steps in osteogenesis, 
including the generation of cartilage Anlagen and initial ossification, proceed 
normally. However, subsequent bone remodelling is aberrant in both [De Vos et al. 
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2018; Holmbeck et al. 1999; Zhou et al. 2000]. Bone formation in mice and zebrafish 
proceeds either by endochondral (within a cartilage precursor), or intramembranous 
ossification (mesenchymal condensation in close association with cartilage) and 
these processes are conserved in humans [Bird et al. 2003; Holmbeck et al. 2006]. 
Knockout of Mmp14 respectively mmp14a/b disturbs both of these processes, 
primarily by impairing the remodeling of non-mineralized collagen matrix, and thereby 
the timely and correct remodeling of cartilage templates [De Vos et al. 2018; 
Holmbeck et al. 1999; Parichy et al. 2009; Schilling 2002; Szabova et al. 2009; 
Witten et al. 2009; Zhou et al. 2000]. Consequently, bone formation, as well as 
skeletal growth, is reduced [De Vos et al. 2018; Holmbeck et al. 1999]. Increased 
osteoclastic bone resorption further contributes to the reduced BMD seen in mice 
[Holmbeck et al. 1999; Zhou et al. 2000]. In Mmp14 KO mice, numbers of osteoclasts 
are increased, and osteoclastic bone resorption was observed adjacent to aberrantly 
remodeled bone-soft tissue interfaces [Hikita et al. 2006; Holmbeck et al. 1999; 
Holmbeck et al. 2006; Zhou et al. 2000]. This process has been suggested by 
Holmbeck and colleagues to act as a compensating mechanism, reducing the stress 
on (peri-) skeletal tissues caused by the impaired soft tissue remodeling, in addition 
to enabling continued growth up to some extent [Holmbeck et al. 1999; Holmbeck et 
al. 2006].  
Additionally, MMP14 has been demonstrated to stimulate the osteogenic 
potential of murine bone marrow stem cells [Holmbeck et al. 1999; Szabova et al. 
2009]. Their commitment to the osteogenic lineage over the chondrogenic and 
adipogenic lineage in 3D in vitro culture is stimulated by catalytic remodeling of the 
ECM by MMP14 [Tang et al. 2013]. Accordingly, mice with mesenchymal progenitor 
cell and skeletal stem cell-specific Mmp14 KO have thickened cartilage, increased 
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bone-marrow adiposity, and delayed membranous ossification and general 
osteopenia without increase in osteoclast number. Their appearance shares 
similarities with the Mmp14 KO mice, including short length and brachycephaly with 
exophthalmos and a short snout (Fig. 1B(iv)) [Tang et al. 2013].  
MOUSE SH3PXD2B MUTANTS SHARE KEY PHENOTYPIC FEATURES WITH 
FTHS  
Murine Sh3pxd2b mutants recapitulate key aspects of FTHS. Moreover, they 
share key phenotypic features with the MMP14 mutants. Mice that lack functional 
Sh3pxd2b due to a truncating mutation (Nee (nose, eyes, ear), Fig. 1B(v)) or gene 
KO (Fig. 1B(vi)) are indistinguishable from their littermates at birth. After weaning, 
mutants develop growth retardation, craniofacial malformations that include 
brachycephaly, a short snout, exophthalmos, and excessive thoracic kyphosis [Dülk 
et al. 2016; Iqbal et al. 2010; Mao et al. 2009]. Although about 20% of Sh3pxd2b KO 
mice died of unknown causes within their first weeks, the life span of surviving KO 
mice, as well as that of Nee mutants, is unaffected [Iqbal et al. 2010]. In both mouse 
models, BMD was reduced and osteogenic differentiation was impaired [Dülk et al. 
2016]. The mice also had various cardiac abnormalities, including septal thinning and 
mitral valve defects [Iqbal et al. 2010].  
 
 MMP2 KNOCKOUT MICE SHARE SOME FEATURES WITH MONA  
In contrast to humans, loss of Mmp2 in mice results in a milder and partially 
transient phenotype. From birth, Mmp2 KO mice are slightly smaller, and develop a 
short snout and a dome-shaped skull with hypertelorism [Inoue et al. 2006; Itoh et al. 
1997; Mosig et al. 2007]. However, the increased intercanthal distance and skull 
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height normalise over time [Mosig et al. 2007]. The BMD is generally and 
progressively reduced in Mmp2 KO mice except in the calvarian bones, whose 
density increased at adult age [Inoue et al. 2006; Mosig et al. 2007]. Notably, Mmp2 
KO was found to impair osteoblast and osteoclast proliferation in vitro, but osteoblast 
activity intensified in Mmp2 KO mice at later age which could, at least in part, explain 
the observed calvarial BMD increase [Inoue et al. 2006; Mosig et al. 2007]. Similar to 
the pathological fractures in several patients with MMP2 mutation, the observed 
osteopenia in Mmp2 KO mice is accompanied by spontaneous tibia fractures [Bader-
Meunier et al. 2016; Inoue et al. 2006; Jeong et al. 2010; Pichler et al. 2016]. Finally, 
adult Mmp2 KO mice have bone erosion underlying articular cartilage destruction of 
the knee [Mosig et al. 2007].  
 
MMP14 PRIMARILY ACTS THROUGH MMP2 IN HUMANS, BUT NOT IN MICE  
Interestingly, the phenotype of Mmp2;Mmp14 double KO mice is more severe 
than that of either single KO. The double KO mice are smaller than their Mmp2 KO 
littermates and have generally smaller skeletal elements [Oh et al. 2004]. Epiphyseal 
vascular ingrowth and cartilage remodelling is impaired in the double KO mice similar 
to Mmp14 KO mice, but these abnormalities are already present perinatally and only 
develop several weeks after birth in Mmp14 KO mice [Oh et al. 2004]. Finally, double 
KO mice die perinatally due to respiratory failure, which the authors attributed to 
impaired skeletal muscle development [Oh et al. 2004]. Our in vitro results show that 
impaired pro-MMP2 activation plays an important role in the MMP14 mutant 
phenotype in humans [De Vos et al. 2018]. However, the milder and partially 
transient phenotype of Mmp2 KO mice indicates that, at least in mice, MMP14 only 
temporarily acts through activation of MMP2 in specific tissues. Also, MMP14 might 
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have additional functions in mice that do not require MMP2 [De Vos et al. 2018; 
Holmbeck et al. 1999; Itoh et al. 2001; Itoh et al. 2006; Itoh et al. 2008; Rozanov et 
al. 2001].  
 
CONCLUSION 
Although the disease mechanism was not elucidated at the time, Borrone and 
colleagues already suspected that the simultaneous involvement of skin, joints, bone 
and heart pointed to involvement of ECM proteins [Borrone et al. 1993]. Indeed, 
mutations of SH3PXD2B, MMP14 and MMP2, the products of which directly 
cooperate in collagen remodelling, were later identified in FTHS, WS and MONA 
patients [Evans et al. 2012; Martignetti et al. 2001; Wilson et al. 2014]. The three 
proteins are conserved from human to fish, and their direct functional link is reflected 
in considerable phenotypic overlap between FTHS, WS and MONA in humans, as 
well as in the corresponding animal models. These models collectively indicate that 
impaired degradation of collagen fibrils is central to the underlying pathology. This is 
reflected in the resulting phenotypes, in which collagen-rich tissues that are heavily 
remodelled during growth and development are primarily affected. It is generally 
accepted that SH3PXD2B is an upstream regulator of MMP14 membrane 
localisation, which in turn activates pro-MMP2 [Murphy et al. 2011; Ohuchi et al. 
1997; Sato et al. 1994; Takino et al. 1995]. Multiple lines of evidence support this 
hierarchical order, with a key role for MMP2 in collagen remodelling in humans. 
Firstly, the phenotype of patients with homozygous mutation of SH3PXD2B, MMP14 
and MMP2 is highly similar. Secondly, we and others have demonstrated in vitro that 
the severity of the phenotype in patients with MMP14 mutation correlates with the 
level of impairment in pro-MMP2 activation [De Vos et al. 2018; Evans et al. 2010; 
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Van Steensel et al. 2007]. Thirdly, Sh3pxd2b KO mice display significant phenotypic 
overlap with Mmp14 KO mice. The phenotype of Mmp14;Mmp2 double KO mice is 
more severe, whereas KO of Mmp2 results in a milder, partially transient phenotype. 
Together, these points suggest that in humans, MMP14 primarily acts through 
MMP2, whereas in mice MMP2 is less important. Only when MMP14 is absent does 
MMP2 loss have an additive effect, which is suggestive of incomplete epistasis.  
In the 9th edition of the Nosology and Classification of Genetic Skeletal 
Disorders, the Fank-Ter Haar syndrome is classified under the “filamin group and 
related disorders”, while MMP2 related pathology is grouped as the Torg-Winchester 
syndrome under the “osteolysis group” [Bonafe et al. 2015]. No MMP14-related 
skeletal disorder is included in the current edition. Given the clinical overlap and 
common pathology, we propose to group the SH3PXD2B, MMP14 and MMP2-
related multicentric osteolytic syndromes in the “defective collagen-remodelling 
spectrum” (DECORS). The central role of impaired collagen remodelling in DECORS 
has therapeutic implications [De Vos et al. 2018]. Bisphosphonates have previously 
been used to treat reduced BMD in patients with MMP14 respectively MMP2 
mutations, with limited therapeutic benefit [De Vos et al. 2018; Phadke et al. 2007; 
Pichler et al. 2016; Van Steensel et al. 2007]. Bisphosphonates primarily act through 
inhibition of osteoclastic bone resorption, which contributes to the observed BDM 
reduction [De Vos et al. 2018; Drake et al. 2010]. However, as the main problem in 
DECORS seems to be defective collagen remodelling, we propose that any 
pharmacotherapy should be aimed at targeting this issue [De Vos et al. 2018]. The 
animal models discussed in this review, in particular the zebrafish, can be used for 
the development and testing of novel therapeutic strategies aimed at correcting the 
defective ECM remodelling [De Vos et al. 2018].  
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    SH3PXD2B  MMP14  MMP2 
Clinical feature    %  n/N  %  n/N  %  n/N 
               
Craniofacial  Coarse facial features  75 12/16  100  4/4  75  25/33 
  Prominent forehead  100 20/20  100  4/4  27  6/22 
  Brachycephaly  100 17/17  33  1/3  42  3/7 
  Hypertelorism  100 20/20  100  2/2  38  8/21 
  Deep-set eyes  0 0/17  100  3/3  19  4/21 
  Anti-mongoloid slant  85 12/14  100  2/2  57  12/21 
  Thick sub-ocular folds  82 14/17  100  3/3  52  12/23 
  Flat nasal bridge  94 16/17  50  2/4  40  9/22 
  Broad mouth  77 14/18  100  3/3  34  8/23 
  Thick lips  80 12/15  100  3/3  75  18/24 
  Small/large mandible  84 16/18  100  4/4  78  18/23 
              
Ophthalmic  Prominent eyes  94 17/18  0  0/2  43  10/23 
  Congenital glaucoma  25 4/16  0  0/2  5  1/20 
  Large cornea  62 10/16  0  0/2  0  0/21 
  Corneal opacities  28 2/7  50  2/4  11  3/27 
              
Dental  Gingival hypertrophy  100 7/7  50  2/4  50  11/22 
  Delayed dentition  100 2/2  50  2/4  0  0/1 
              
Skeletal  Short stature  75 3/4  50  2/4  60  18/30 
  Prominent anterior fontanel  100 17/17  100  2/2  0  0/1 
  Open sutures  6 4/6  100  1/1  0  0/4 
  Kyphoscoliosis  65 11/17  67  2/3  43  7/16 
  Vertebral anomalies  87 7/8  75  3/4  47  8/17 
  Brachydactyly  100 20/20  50  2/4  71  15/21 
  Bowing of long bones  78 7/9  33  1/3  87  7/8 
  Joint destruction  0 0/2  50  2/4  100  35/35 
  Osteolysis  100 7/7  50  2/4  100  36/36 
  Reduced BMD  100 4/4  100  4/4  100  36/36 
  Flexion deformity / contractures  69 11/16  100  3/3  96  32/33 
  Talipes equinovares  67 10/15  0  0/3  16  1/6 
  Starts in small joints  100 1/1  50  2/4  100  20/20 
              
Cutaneous  Subcutaneous nodules  75 3/4  50  2/4  80  28/35 
  Thickened skin  100 3/3  100  2/2  75  6/8 
  Acne  25 2/8  100  2/2  0  0/19 
              
Cardiac  MVP / regurgitation  55 11/20  100  2/2  5  1/19 
  Outflow tract abnormalities  46 6/13  0 0/2  11 2/19 
  VSD  35 7/20  0  0/4  22  4/18 
              
Developmental  Cognitive disability  8 1/13  0  0/4  0  0/16 
  Motor disability  56 9/16  50  2/4  14  2/14 
De Vos et al. 39 
Prevalence is shown as the number (n) or percentage (%) of patients with a feature 
out of the total number of individuals (N) that were examined for that feature. Details 
per original report are listed in Supplemental Table I [Al Aqeel et al. 2000; Al Kaissi et 
al. 2011; Azzollini et al. 2014; Bader-Meunier et al. 2016; Bendon et al. 2012; 
Bhavani et al. 2016; Borrone et al. 1993; Castberg et al. 2013; Chang et al. 2017; 
Eisenstein et al. 1998; Ekbote et al. 2014; Gok et al. 2010; Hamel et al. 1995; Iqbal et 
al. 2010; Jeong et al. 2010; Maas et al. 2004; Martignetti et al. 2001; Mégarbané et 
al. 1997; Phadke et al. 2007; Pichler et al. 2016; Prapanpoch et al. 1992; Rouzier et 
al. 2006; Temtamy et al. 2012; Ter Haar et al. 1982; Tuysuz et al. 2009; Vanatka et 
al. 2010; Van Steensel et al. 2007; Wilson et al. 2014; Winchester et al. 1969; Zankl 
et al. 2005; Zankl et al. 2007; Zrhidri et al. 2017].  
Abbreviations: BMD, bone mineral density; MVP, mitral valve prolapse; NR, no 
record; VSD, ventricle septum defect.  
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Supplemental Table I – Detailed clinical features of included individuals with identified homozygous SH3PXD2B, MMP14 or MMP2 
mutation.  
















































































































































































































































































Clinical feature  n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N %  n/N n/N n/N %  n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N % 
Sex                                     
Male  2/3 2/2 1/2 0/1 4/5 2/3 1/1 1/2 0/1 13/20 65  0/2 2/2 2/4 50  1/2 0/1 0/1 0/2 1/2 1/3 2/2 0/1 0/1 0/3 1/3 1/1 0/1 1/2 10/13 0/1 18/39 46 
Craniofacial                                     
Coarse facies  1/3 2/2 1/1 1/1 3/3 3/3 1/1 0/2 - 12/16 75  2/2 2/2 4/4 100  1/2 0/1 1/1 2/2 2/2 0/2 0/1 0/1 0/1 1/1 3/3 1/1 1/1 1/1 11/13 1/1 25/33 75 
Prominent forehead  3/3 2/2 2/2 1/1 5/5 3/3 1/1 2/2 1/1 20/20 100  2/2 2/2 4/4 100  - - 0/1 0/2 1/1 0/2 - - - 1/1 0/1 0/1 1/1 - 3/12 - 6/22 27 
Brachycephaly  3/3 1/1 2/2 1/1 5/5 3/3 1/1 - 1/1 17/17 100  1/1 0/2 1/3 33  2/2 - 0/1 0/1 - - - - 0/1 - - 0/1 1/1 - - - 3/7 42 
Hypertelorism  3/3 2/2 2/2 1/1 5/5 3/3 1/1 2/2 1/1 20/20 100  - 2/2 2/2 100  2/2 - 0/1 2/2 0/1 2/2 - - - 0/1 - 0/1 - - 2/11 - 8/21 38 
Deep-set eyes  0/3 0/2 0/2 0/1 0/3 0/3 0/1 0/2 - 0/17 0  1/1 2/2 3/3 100  0/2 - 0/1 0/2 0/1 0/2 - - - - - 0/1 - - 4/12 - 4/21 19 
Anti-mongoloid slant  1/3 1/1 2/2 1/1 1/3 3/3 1/1 2/2 - 12/14 85  - 2/2 2/2 100  0/1 - 1/1 2/2 0/1 1/2 - - - 1/1 - 1/1 - - 6/12 - 12/21 57 
Prominent eyes  3/3 - 2/2 1/1 5/5 3/3 1/1 1/2 1/1 17/18 94  - 0/2 0/2 0  2/2 - 0/1 0/2 0/1 1/2 - - - 1/1 2/2 0/1 - - 4/11 - 10/23 43 
Full cheeks  1/3 2/2 1/2 1/1 5/5 3/3 1/1 - 1/1 15/18 83  1/1 2/2 3/3 100  1/2 1/1 0/1 2/2 0/1 1/2 - - - 0/1 1/2 1/1 1/1 - 7/12 - 15/26 57 
Thick subocular fold  0/3 2/2 2/2 1/1 3/3 3/3 1/1 2/2 - 14/27 82  1/1 2/2 3/3 100  1/2 1/1 1/1 1/1 1/1 1/2 - - - 1/1 1/1 1/1 - - 3/12 - 12/23 52 
Flat nasal bridge  3/3 1/2 2/2 1/1 3/3 3/3 1/1 2/2 - 16/17 94  2/2 0/2 2/4 50  0/1 1/1 0/1 0/2 1/1 0/2 - - - 1/1 - 0/1 1/1 - 5/11 - 9/22 40 
Anteverted nostrils  2/2 2/2 2/2 1/1 3/5 0/3 0/1 2/2 0/1 12/19 63  1/1 0/2 1/3 33  1/2 1/1 0/1 0/2 1/1 0/2 - - - - 1/1 0/1 1/1 - 7/11 - 12/23 52 
Short philthrum  1/3 0/2 0/2 1/1 0/3 0/3 0/1 1/2 - 3/17 18  1/1 2/2 3/3 100  0/2 1/1 1/1 2/2 1/1 0/2 - - - 0/1 0/1 1/1 1/1 - 7/12 - 14/25 56 
Broad mouth  1/3 2/2 0/2 1/1 5/5 3/3 1/1 - 1/1 14/18 77  1/1 2/2 3/3 100  1/2 0/1 1/1 2/2 1/1 0/2 - - - 0/1 0/1 0/1 - - 3/11 - 8/23 34 
Thick lips  3/3 2/2 2/2 1/1 1/3 3/3 0/1 - - 12/15 80  1/1 2/2 3/3 100  2/2 0/1 1/1 2/2 2/2 1/2 - - - - 1/1 1/1 - - 8/12 - 18/24 75 
Macroglossia  - 0/1 - - - - - - - 0/1 0  2/2 0/2 2/4 50  - - - - 2/2 - - - - - - - 0/1 - - - 2/3 66 
Prominent lower jaw  0/3 2/2 0/2 0/1 0/5 0/3 0/1 - 0/1 2/17 12  0/1 2/2 2/3 67  0/2 1/1 0/1 - 1/1 0/2 - - - 0/1 1/1 1/1 0/1 - 6/12 - 10/23 43 
Micrognathia  3/3 0/2 2/2 1/1 5/5 1/3 1/1 - 1/1 14/18 78  2/2 0/2 2/4 50  1/2 0/1 0/1 - 0/1 2/2 - - - 1/1 - 0/1 1/1 - 3/12 - 8/22 36 
Protruding ears  0/3 2/2 1/2 1/1 2/2 3/3 0/1 0/1 1/1 10/15 67  - 0/2 0/2 0  1/1 - 1/1 0/2 0/1 1/2 - - - 0/1 1/1 1/1 - - 4/12 - 9/22 40 
Ophthalmic                                     
Congenital glaucoma  1/1 - 2/2 0/1 1/5 0/3 0/1 0/2 0/1 4/16 25  - 0/2 0/2 0  0/1 0/1 - - - 0/2 1/1 - - - 0/2 - 0/1 - 0/12 - 1/20 5 
Large cornea  1/1 - 1/2 0/1 5/5 0/3 0/1 2/2 1/1 10/16 62  - 0/2 0/2 0  0/1 0/1 - - 0/1 0/2 0/1 - - - 0/2 - 0/1 - 0/12 - 0/21 0 
Corneal opacities  - - 2/2 0/1 - 0/3 0/1 - - 2/7 28  2/2 0/2 2/4 50  0/1 0/1 - 0/2 0/1 1/2 0/1 0/1 0/1 - 0/2 - 0/1 1/2 1/12 - 3/27 11 
Dental                                     
Broad alveolar ridges  - - - 1/1 3/5 - 1/1 - - 5/7 71  - - - -  - - - - - - - - - - - - 0/1 - - - 0/1 0 
Gingival hypertrophy  - 2/2 2/2 - - - 1/1 2/2 - 7/7 100  2/2 0/2 2/4 50  0/1 0/1 - - 2/2 2/2 - - - - 3/3 - 0/1 - 3/11 1/1 11/22 50 
Delayed dentition  - 1/1 - - - - 1/1 - - 2/2 100  2/2 0/2 2/4 50  - - - - - - - - - - - - 0/1 - - - 0/1 0 
Irregularly spaced teeth  - - - - - - - - - - -  2/2 0/2 2/4 50  0/1 - - - - - - - - - - 0/1 0/1 - - - 0/3 0 
Misaligned teeth  - - - - - - - - - - -  1/1 1/2 2/3 67  0/1 - - - - - - - - - - 0/1 0/1 - - - 0/3 0 
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Supplemental Table I (continued). 
















































































































































































































































































Clinical feature  n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N %  n/N n/N n/N %  n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N n/N % 
Skeletal                                     
Short stature  - 1/1 1/2 1/1 - - - - - 3/4 75  2/2 0/2 2/4 50  2/2 - 1/1 2/2 2/2 1/2 2/2 1/1 1/1 3/3 0/3 0/1 1/1 0/2 2/7 - 18/30 60 
Prominent anterior fontanel  3/3 - 2/2 1/1 5/5 2/3 - 2/2 1/1 17/17 100  2/2 - 2/2 100  - - - - - - - - - - - - 0/1 - - - 0/1 0 
Open sutures  - - 2/2 - - 2/3 0/1 - - 4/6 67  1/1 - 1/1 100  - - - - - - - - 0/1 - 0/2 - 0/1 - - - 0/4 0 
Kyphoscoliosis  1/3 2/2 - 0/1 4/5 1/3 1/1 2/2 1/1 11/17 65  1/1 1/2 2/3 67  - - 0/1 2/2 - - - - 1/1 - 1/1 0/1 0/1 1/2 2/7 - 7/16 43 
Vertebral anomalies  - 2/2 2/2 0/1 - - 1/1 2/2 - 7/8 87  2/2 1/2 3/4 75  0/1 - 1/1 2/2 - - - 1/1 1/1 - 0/2 - 0/1 - 2/7 1/1 8/17 47 
Brachydactyly  3/3 2/2 2/2 1/1 5/5 3/3 1/1 2/2 1/1 20/20 100  0/2 2/2 2/4 50  2/2 - 1/1 2/2 1/1 2/2 0/1 - 1/1 1/1 2/2 0/1 - - 3/7 - 15/21 71 
Bowing of long bones  - 1/1 - 1/1 3/5 - 1/1 - 1/1 7/9 78  1/1 0/2 1/3 33  - - - 2/2 2/2 1/2 - - - - - - - - 2/2 - 7/8 87 
Limited motion  - 2/2 2/2 1/1 - - 1/1 - - 6/6 100  2/2 0/2 2/4 50  2/2 1/1 1/1 2/2 2/2 2/2 2/2 1/1 - 3/3 2/2 1/1 1/1 2/2 13/13 1/1 36/36 100 
Joint destruction  - 0/2 - - - - - - - 0/2 0  2/2 0/2 2/4 50  2/2 1/1 1/1 2/2 1/1 2/2 1/1 1/1 1/1 3/3 3/3 1/1 1/1 2/2 13/13 - 35/35 100 
Osteolysis  3/3 2/2 - - - - - 2/2 - 7/7 100  2/2 0/2 2/4 50  - 1/1 1/1 2/2 2/2 3/3 2/2 1/1 1/1 2/2 3/3 1/1 1/1 2/2 13/13 1/1 36/36 100 
Reduced bone mineral density  - 2/2 - 1/1 - - 1/1 - - 4/4 100  2/2 2/2 4/4 100  2/2 - 1/1 2/2 2/2 3/3 2/2 1/1 1/1 2/2 2/2 1/1 1/1 2/2 13/13 1/1 36/36 100 
Path. fractures/imp. healing  - - - - - - - - - - -  - - - -  - 1/1 - - - - - 1/1 - 1/1 0/1 - - - - 1/1 4/5 80 
Arthralgia  - - - - - - - - - - -  1/1 0/2 1/3 33  2/2 1/1 - - 1/1 - 0/2 - - 1/1 1/3 - - 1/1 10/12 - 17/23 73 
Flex. deformity / contractures  - 2/2 2/2 - 2/5 1/3 1/1 2/2 1/1 11/16 69  1/1 2/2 3/3 100  2/2 1/1 - 2/2 2/2 1/2 2/2 - - 3/3 2/2 1/1 1/1 1/1 13/13 1/1 32/33 96 
Club feet  2/3 0/1 1/2 1/1 2/3 2/3 1/1 - 1/1 10/15 67  0/1 0/2 0/3 0  0/2 0/1 - - 0/1 - - - - - - 0/1 1/1 - - - 1/6 16 
Enlarged metaphyses  - - - - - - - - - - -  1/2 0/2 1/4 25  0/2 - - - - - 2/2 - - 1/1 - - - - - - 3/5 60 
Starts in small joints  - - - 1/1 - - - - - 1/1 100  0/2 2/2 2/4 50  2/2 1/1 1/1 2/2 2/2 2/2 2/2 - 1/1 1/1 2/2 1/1 1/1 1/1 - 1/1 20/20 100 
Progressive to large joints  - - - - - - - - - - -  0/2 0/2 0/4 0  2/2 1/1 1/1 2/2 1/1 2/2 2/2 - 1/1 1/1 2/2 - 1/1 1/1 - 1/1 18/18 100 
Prominent coccyx  3/3 0/1 2/2 1/1 3/5 1/3 - 2/2 1/1 13/18 72  - 0/2 0/2 0  - - - - - - - - - - - - - - - - - - 
Cutaneous                                     
Subcutaneous nodules  - 1/1 - - - 2/3 - - - 3/4 75  2/2 0/2 2/4 50  2/2 1/1 0/1 0/2 1/1 2/2 2/2 0/1 0/1 0/1 3/3 1/1 1/1 2/2 12/13 1/1 28/35 80 
Thickened skin  - 2/2 - - - - 1/1 - - 3/3 100  - 2/2 2/2 100  2/2 - - 1/2 - - - - - 0/1 2/2 - - - - 1/1 6/8 75 
Acne  - 2/2 - - - 0/3 0/1 0/2 - 2/8 25  - 2/2 2/2 100  0/2 - 0/1 - 0/1 0/2 - - - - - 0/1 - - 0/12 - 0/19 0 
Cardiac                                     
Myocardial damage  0/3 - 0/2 - - - - - - 0/5 0  2/2 0/2 2/4 50  - - - - - - - - - - - - - 0/1 - - 0/1 0 
Mitral valve prolapse/regurg.  1/3 2/2 0/2 1/1 2/5 3/3 1/1 1/2 0/1 11/20 55  - 2/2 2/2 100  - - - - - 0/2 0/1 - - 0/2 1/1 0/1 0/1 0/2 0/9 - 1/19 5 
Outflow tract anomalies  1/1 0/2 0/2 0/1 1/1 2/3 0/1 2/2 0/1 6/13 46  - 0/2 0/2 0  - - - - - 1/2 0/1 - - 0/2 0/1 1/1 0/1 0/2 0/9 - 2/19 11 
Ventricle septum defect  1/3 0/2 1/2 1/1 3/5 0/3 0/1 1/2 0/1 7/20 35  - 0/2 0/4 0  - - - - - 1/2 0/1 - - 1/2 - 1/1 0/1 0/2 1/9 - 4/18 22 
Developmental                                     
Cognitive disability  0/3 0/2 0/1 1/1 - 0/3 0/1 0/2 - 1/13 8  0/2 0/2 0/4 0  0/1 0/1 0/1 0/2 0/1 0/2 0/2 0/1 0/1 0/3 0/1 0/1 - 0/2 - - 0/16 0 
Motor disability  3/3 0/2 1/1 1/1 2/3 1/3 0/1 1/2 - 9/16 56  2/2 0/2 2/4 50  1/1 - - - 0/1 0/2 0/2 - - 0/3 0/1 0/1 1/1 0/2 - - 2/14 14 
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A single individual (patient X-3 as reported by Ter Haar et al.) was included even 
though no genetic analysis was performed, as her phenotype was identical to that of 
her brother who had a homozygous SH3PXD2B mutation as identified by Iqbal et al. 
[Iqbal et al. 2010; Ter Haar et al. 1982]. Another patient from the same report (patient 
X-10 from Ter Haar et al.) was excluded, as no genetic analysis was performed and 
this individual is not closely related to the two other patients (7th cousins). Prevalence 
of clinical features is shown as the number (n) or percentage (%) of patients with a 
feature out of the total number of individuals (N) that were examined for that feature, 
both per report as well as summarized per gene. Dash (-) indicates no record of that 
particular feature in the corresponding report. Abbreviations: flex, flexion; imp, 
impaired; path, pathological; regurg, regurgitation. 
 
FIGURE LEGENDS 
Figure 1 – Mutation of SH3PXD2B, MMP14 and MMP2 results in a similar 
phenotype in humans, mice and zebrafish. A, Mutation of SH3PXD2B (panel i), 
MMP14 (panel ii) and MMP2 (panel iii) in patients all result in skeletal dysplasia with 
significant clinical overlap and highly similar facial features (see Table 1 for details). 
Note the presence of a broad forehead, downslanting palpebral fissures with 
characteristic subocular fold, and broad mouth with full lips. B, murine Mmp14 
(panels i-iv) and Sh3pxd2b (panels v and vi) mutants share key aspects of the 
phenotype with patients including craniofacial malformations encompassing a 
relatively large neurocranium and a small snout. C, in zebrafish, knockout (KO) of 
mmp14a/b (3-month-old adult fish) results in a similar phenotype, including a short 
head with short snout and exophthalmos. Images in (A) are reproduced from Wilson 
et al. (i), Van Steensel et al. (ii) and Zankl et al. (iii), respectively; images in (B) are 
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reproduced from The Mouse Mutant Resource (The Jackson laboratory, Bar Harbor, 
Maine, 2007; available via www.informatics.jax.org/image/pheno/MGI: 5634011) (i), 
Holmbeck et al (iii), Tang et al. (iv), Mao et al. (v) and Iqbal et al. (vi); image in (C) is 
reproduced from De Vos et al.; all with permission [Curtain et al. 2012; De Vos et al. 
2018; Holmbeck et al. 1999; Iqbal et al. 2010; Mao et al. 2009; Tang et al. 2013; Van 
Steensel et al. 2007; Wilson et al. 2014; Zankl et al. 2005].  
 
Figure 2 – SH3PXD2B, MMP14 and MMP2 cooperate in podosome function. A, 
schematic overview of podosome formation. Binding of β1-integrin and growth factor 
receptors (GFR) to their respective substrates leads to the activation of the kinase 
SRC (panel i) [Hoshino et al. 2013; Murphy et al. 2011]. Activated SRC 
phosphorylates SH3PXD2B and its partners SH3PXD2A and cortactin, which are 
subsequently recruited to the plasma membrane at sites rich in phosphatidylinositol 
3,4-bisphosphate (PI3,4P2) near focal adhesions. Here, they interact with multiple 
actin regulators to stimulate actin polymerization and branching during podosome 
assembly (panel ii) [Buschman et al. 2009; Holmbeck et al. 2003; Hoshino et al. 
2013; Iqbal et al. 2010; Murphy et al. 2011]. SH3PXD2A furthermore recruits 
cortactin to the forming podosome, which in turn initiates the secretion of soluble pro-
MMP2. SH3PXD2B recruits active MMP14 from intracellular stores to the nascent 
podosome membrane during podosome maturation (panel iii) [Iqbal et al. 2010; 
Murphy et al. 2011; Poincloux et al. 2009]. MMP14 cleaves and thereby activates 
secreted pro-MMP2, and together initiate focal ECM degradation [Bendon et al. 
2012; Buschman et al. 2009; Massova et al. 1998; Murphy et al. 2011]. Concurrent 
protrusion of the podosome into the extracellular space is controlled by non-muscle 
myosin-II [Gawden-Bone et al. 2010]. B, schematic drawing of a podosome at the 
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ventral cell surface in 2D culture, highlighting the spatial relationship of the key 
players (insert). Panel (B) is adapted from Murphy et al., with permission [Murphy et 
al. 2011]. 
